Filtered By:
Condition: Diabetes
Procedure: Liver Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 56 results found since Jan 2013.

E-260 Bilateral cerebral arteriovenous shunting through pial and perforating vessels with multiple strokes and intraparenchymal hemorrhages in a patient with hepatopulmonary syndrome
This study presents a unique case of a 54-year-old male patient with a history of stroke, liver cirrhosis, portal vein thrombosis, hypertension, diabetes, and bladder cancer, who experienced multiple episodes of intracranial hemorrhages, stroke and worsening confusion over the past five years. The patient‘s clinical presentation raised suspicion for an underlying occult vasculopathy. Digital subtraction angiography (DSA) revealed multiple curvilinear, irregular, bilateral pial vessels with early high-flow arteriovenous shunting, consistent with vascular shunting that is associated with liver cirrhosis. The patient&ls...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Aljeradat, B., Koneru, M., Oliveira, R., Shaikh, H. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Atherosclerosis on CT coronary angiography and risk of long-term cardiovascular events post liver transplantation
CONCLUSION: The standardized CAD-RADS classification on CTCA predicted the occurrence of cardiovascular outcomes following LT, with a potential to increase utilization of preventive cardiovascular therapies.PMID:37432891 | DOI:10.1097/LVT.0000000000000215
Source: Atherosclerosis - July 11, 2023 Category: Cardiology Authors: Thalys Sampaio Rodrigues Anoop N Koshy Paul J Gow Laurence Weinberg Benjamin Cailes Adam Testro Gerard Smith Han S Lim Andrew W Teh Ruth P Lim Omar Farouque Source Type: research

Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news

Characteristics of stroke after liver and kidney transplantation
ConclusionsIn-hospital, perioperative, and hemorrhagic strokes were more common in the LT group than in the KT group. Ischemic stroke subtypes did not differ significantly between the two groups and undetermined etiology was the most common cause of ischemic stroke in both groups. High mortality after stroke was noted in transplantation patients and was associated with in-hospital stroke.
Source: Frontiers in Neurology - March 22, 2023 Category: Neurology Source Type: research

Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota. Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research

Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
CONCLUSIONS: Statins appear to be generally well-tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.PMID:36800538 | DOI:10.2215/CJN.0000000000000124
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 17, 2023 Category: Urology & Nephrology Authors: Sunjae Bae JiYoon B Ahn Kmd Corey Joseph Ryan Whisler Mark A Schnitzler Krista L Lentine Bernard S Kadosh Dorry L Segev Mara A McAdams-DeMarco Source Type: research

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Eur Respir Rev. 2022 Nov 2;31(166):220098. doi: 10.1183/16000617.0098-2022. Print 2022 Dec 31.ABSTRACTBACKGROUND: As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations.METHODS: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to sever...
Source: Respiratory Care - November 2, 2022 Category: Respiratory Medicine Authors: Constantine I Vardavas Alexander G Mathioudakis Katerina Nikitara Kimon Stamatelopoulos Georgios Georgiopoulos Revati Phalkey Jo Leonardi-Bee Esteve Fernandez Dolors Carnicer-Pont J ørgen Vestbo Jan C Semenza Charlotte Deogan Jonathan E Suk Piotr Kramarz Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news